Showing 4681-4690 of 20465 results for "".
- Ensitrelvir Versus Nirmatrelvir in COVID-19 Viral Clearancehttps://reachmd.com/news/ensitrelvir-versus-nirmatrelvir-in-covid-19-viral-clearance/2487153/Key Takeaways Both 5-day oral antiviral regimens were associated with faster oropharyngeal SARS-CoV-2 clearance than no study drug, and nirmatrelvir showed the faster signal head to head. The trial enrolled low-risk adult outpatients early in illness a
- Four-Year RHONE-X Data Show Durable Faricimab Outcomes in DMEhttps://reachmd.com/news/four-year-rhone-x-data-show-durable-faricimab-outcomes-in-dme/2487161/Key Takeaways Visual acuity gains of about 10 to 11 letters were maintained, alongside sustained CST reductions and DME absence by study definition (CST < 325 μm) in more than 90% of patients at study end. About 80% of patients reached intervals of
- Foot Core Training Plus Hip And Knee Strengthening For Patellofemoral Painhttps://reachmd.com/news/foot-core-training-plus-hip-and-knee-strengthening-for-patellofemoral-pain/2487163/Key Takeaways Adding foot-core training to hip–knee strengthening was associated with greater post-intervention pain reduction and higher function scores than hip–knee strengthening alone. The experimental group showed lower hip adduction and knee valg
- Blood X Chromosome Loss Linked to Lower Natural Conception Oddshttps://reachmd.com/news/blood-x-chromosome-loss-linked-to-lower-natural-conception-odds/2487133/Key Takeaways Higher hematopoietic LOX in peripheral blood was associated with a lower likelihood of natural conception in this case-control cohort. Peripheral-blood %LOX increased with age and did not track with AMH or FSH levels. No clear as
- BE BOLD: Bimekizumab Tops Risankizumab for ACR50 Outcomeshttps://reachmd.com/news/be-bold-bimekizumab-tops-risankizumab-for-acr50-outcomes/2487139/New phase 3 data from the BE BOLD trial indicated that bimekizumab (BIMZELX) achieved superior joint efficacy compared with risankizumab (SKYRIZI) in adults with active psoriatic arthritis (PsA), according to a press release from the manufacturer.
- CMSC and NeurologyLive Name 2026 Giants of Multiple Sclerosishttps://reachmd.com/news/cmsc-and-neurologylive-name-2026-giants-of-multiple-sclerosis/2487138/Key Takeaways Seven honorees were named across seven disciplines in the 2026 class. Finalists were determined by an advisory board, and category inductees were chosen by a selection committee of more than 30 MS professionals. Patricia K. Coyle
- From SCALE 2026: Practical Strategies for Treating GLP-1–Related Aesthetic Changeshttps://reachmd.com/news/from-scale-2026-practical-strategies-for-treating-glp-1related-aesthetic-changes/2487118/At the 2026 Music City SCALE meeting, Terrence Keaney, MD, discussed how dermatologists can proactively address facial aging, skin laxity, hair loss, and muscle loss associated with GLP-1–mediated weight reduction, outlining a practical framework for managing some of the aesthetic issues related
- Low-Dose Naltrexone in Major Depressive Disorder: Trial Findingshttps://reachmd.com/news/low-dose-naltrexone-mdd/2487123/Key Takeaways In patients with moderate major depressive disorder, adjunctive low-dose naltrexone was not associated with greater improvement than placebo. No effect was seen on hsCRP or on BDI-II, BADS, SF-36, POMS, and SicknessQ measures, and baselin
- Global Burden Of Nontraumatic Subarachnoid Hemorrhagehttps://reachmd.com/news/global-burden-of-nontraumatic-subarachnoid-hemorrhage/2487179/Key Takeaways Nontraumatic subarachnoid hemorrhage carried a large global burden in 2021, with lower age-standardized incidence, prevalence, mortality, and disability-adjusted life-year rates than in 1990 even as absolute incident and prevalent case counts rose
- Study: Hair Care Regimen May Enhance Minoxidil Response in Women With Hair Losshttps://reachmd.com/news/seen-study-suggests-hair-care-regimen-may-enhance-minoxidil-response-in-women-with-hair-loss/2487130/SEEN Hair Care presented new clinical findings at the 2026 Music City Symposium for Cosmetic Advances and Laser Education (SCALE), suggesting that a non-comedogenic, non-irritating hair care regimen may improve outcomes with topical minoxidil 5% foam in women with